The use of biologic disease-modifying antirheumatic drugs does not increase surgical site infection or delayed wound healing after orthopaedic surgeries for rheumatoid arthritis
Modern Rheumatology · 2025
DOI: 10.1093/mr/roae089 ↗Kurz gefasst
Fachartikel in der Zeitschrift Modern Rheumatology, 2025. Verfasst von Yohei Kiso und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Surgical Wound Infection, Antirheumatic Agents, Wound Healing. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Wundversorgung
Abstract (Originalsprache)
Objective
To investigate the effect of the use of biologic disease-modifying antirheumatic drugs (bDMARDs) on surgical site infection (SSI) and delayed wound healing (DWH) in rheumatoid arthritis (RA) patients undergoing orthopaedic surgery.
Methods
We retrospectively reviewed the records of 965 elective orthopaedic procedures undertaken in RA patients. The incidences of SSI and DWH were compared between the bDMARDs user and nonuser groups. Subsequently, univariate and multivariate logistic regression analyses were performed to evaluate risk factors for SSI and DWH after propensity score matching. The incidence of postoperative flare-up was also examined.
Results
In 965 procedures, SSI and DWH were identified in 12 and 28 cases, respectively. SSI and DWH were identified in 3 and 17 of 414 procedures treated with bDMARDs, respectively. Flare-up occurred in 21 cases. Propensity score matching identified 315 cases in both groups, with no significant difference in incidence between the two groups. No risk factors for SSI were identified, whereas age, diabetes mellitus, foot and ankle surgery, and a history of musculoskeletal-related infection were identified as risk factors for DWH.
Conclusion
The use of bDMARDs was not associated with an increased incidence of SSI or DWH, with the incidence of flare-up being relatively low.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
- Locomotive Pain Center, Okayama University Hospital, Okayama, Japan.
- Department of Orthopaedic Surgery, Kurashiki Sweet Hospital, Okayama, Japan.
- Department of Orthopaedic Surgery, Okayama University Hospital, Okayama, Japan.
ORCID-Profile: Yohei Kiso, Keiichiro Nishida
Zitieren
APA
Kiso, Y., Nishida, K., Harada, R., Nasu, Y., Nakahara, R., Hotta, Y., Naniwa, S., & Ozaki, T. (2025). The use of biologic disease-modifying antirheumatic drugs does not increase surgical site infection or delayed wound healing after orthopaedic surgeries for rheumatoid arthritis. Modern Rheumatology. https://doi.org/10.1093/mr/roae089
Vancouver
Kiso Y, Nishida K, Harada R, Nasu Y, Nakahara R, Hotta Y, et al. The use of biologic disease-modifying antirheumatic drugs does not increase surgical site infection or delayed wound healing after orthopaedic surgeries for rheumatoid arthritis. Modern Rheumatology. 2025. doi:10.1093/mr/roae089
BibTeX
@article{Kiso2025,
author = {Kiso, Yohei and Nishida, Keiichiro and Harada, Ryozo and Nasu, Yoshihisa and Nakahara, Ryuichi and Hotta, Yoshifumi and Naniwa, Shuichi and Ozaki, Toshifumi},
title = {The use of biologic disease-modifying antirheumatic drugs does not increase surgical site infection or delayed wound healing after orthopaedic surgeries for rheumatoid arthritis},
journal = {Modern Rheumatology},
year = {2025},
doi = {10.1093/mr/roae089}
}
EUVIMED